Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 5.33
CEMP's Cash to Debt is ranked higher than
67% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. CEMP: 5.33 )
CEMP' s 10-Year Cash to Debt Range
Min: 1.12   Max: No Debt
Current: 5.33

Equity to Asset 0.63
CEMP's Equity to Asset is ranked higher than
68% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CEMP: 0.63 )
CEMP' s 10-Year Equity to Asset Range
Min: 0.63   Max: 0.81
Current: 0.63

0.63
0.81
F-Score: 3
Z-Score: 1.88
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -549.34
CEMP's Operating margin (%) is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. CEMP: -549.34 )
CEMP' s 10-Year Operating margin (%) Range
Min: -549.34   Max: -549.34
Current: -549.34

Net-margin (%) -576.41
CEMP's Net-margin (%) is ranked higher than
58% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. CEMP: -576.41 )
CEMP' s 10-Year Net-margin (%) Range
Min: -576.41   Max: -576.41
Current: -576.41

ROE (%) -64.36
CEMP's ROE (%) is ranked higher than
59% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -20.60 vs. CEMP: -64.36 )
CEMP' s 10-Year ROE (%) Range
Min: -64.36   Max: -41.94
Current: -64.36

-64.36
-41.94
ROA (%) -45.49
CEMP's ROA (%) is ranked higher than
62% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. CEMP: -45.49 )
CEMP' s 10-Year ROA (%) Range
Min: -125.87   Max: -34.25
Current: -45.49

-125.87
-34.25
ROC (Joel Greenblatt) (%) -31101.45
CEMP's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. CEMP: -31101.45 )
CEMP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -53344.19   Max: -12967.36
Current: -31101.45

-53344.19
-12967.36
» CEMP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

CEMP Guru Trades in Q2 2013

Jean-Marie Eveillard 1,308,701 sh (New)
» More
Q3 2013

CEMP Guru Trades in Q3 2013

Jean-Marie Eveillard 1,308,701 sh (unchged)
» More
Q4 2013

CEMP Guru Trades in Q4 2013

Jean-Marie Eveillard 780,275 sh (-40.38%)
» More
Q1 2014

CEMP Guru Trades in Q1 2014

Jean-Marie Eveillard Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CEMP

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-03-31 Sold Out 0.03%$11.01 - $14.92 $ 9.42-24%0
Jean-Marie Eveillard 2013-12-31 Reduce -40.38%0.02%$10.1 - $13.5 $ 9.42-22%780275
Jean-Marie Eveillard 2013-06-30 New Buy0.03%$6.03 - $8.13 $ 9.4236%1308701
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.80
CEMP's P/B is ranked higher than
72% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 5.51 vs. CEMP: 5.80 )
CEMP' s 10-Year P/B Range
Min: 2.35   Max: 7.09
Current: 5.8

2.35
7.09
P/S 27.25
CEMP's P/S is ranked higher than
69% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. CEMP: 27.25 )
CEMP' s 10-Year P/S Range
Min: 24.03   Max: 61.57
Current: 27.25

24.03
61.57
EV-to-EBIT -4.81
CEMP's EV-to-EBIT is ranked higher than
78% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CEMP: -4.81 )
CEMP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -4.81

Current Ratio 7.99
CEMP's Current Ratio is ranked higher than
85% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. CEMP: 7.99 )
CEMP' s 10-Year Current Ratio Range
Min: 2.48   Max: 30.34
Current: 7.99

2.48
30.34
Quick Ratio 7.99
CEMP's Quick Ratio is ranked higher than
86% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. CEMP: 7.99 )
CEMP' s 10-Year Quick Ratio Range
Min: 2.48   Max: 30.34
Current: 7.99

2.48
30.34

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.50
CEMP's Price/Net Cash is ranked higher than
89% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 65.19 vs. CEMP: 6.50 )
CEMP' s 10-Year Price/Net Cash Range
Min: 2.64   Max: 7.91
Current: 6.5

2.64
7.91
Price/Net Current Asset Value 6.20
CEMP's Price/Net Current Asset Value is ranked higher than
88% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 44.88 vs. CEMP: 6.20 )
CEMP' s 10-Year Price/Net Current Asset Value Range
Min: 2.63   Max: 7.55
Current: 6.2

2.63
7.55
Price/Tangible Book 5.80
CEMP's Price/Tangible Book is ranked higher than
79% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 8.78 vs. CEMP: 5.80 )
CEMP' s 10-Year Price/Tangible Book Range
Min: 2.61   Max: 7.13
Current: 5.8

2.61
7.13
Price/Median PS Value 0.60
CEMP's Price/Median PS Value is ranked higher than
94% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. CEMP: 0.60 )
CEMP' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.19
Current: 0.6

0.7
1.19

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9C1.Germany
Cempra Inc was formed as Cempra Holdings, LLC, a limited liability company under the laws of the State of Delaware, on May 16, 2008. Cempra Holdings, LLC was formed in connection with a reorganization whereby the stockholders of Cempra Pharmaceuticals, Inc., a corporation formed under the laws of the State of Delaware on November 18, 2005, exchanged their shares of Cempra Pharmaceuticals, Inc. stock for shares of Cempra Holdings, LLC, pursuant to a merger of a subsidiary of Cempra Holdings LLC with and into Cempra Pharmaceuticals, Inc., as a result of which Cempra Pharmaceuticals, Inc. became a wholly-owned subsidiary of Cempra Holdings, LLC.. The company is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical unmet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and skin and skin structure infections. Its program is CEM-101, which the company is developing in intravenous, or IV, and oral formulations for the treatment of community-acquired bacterial pneumonia, or CABP. The company is recently completed a successful Phase 2 clinical trial in which the oral formulation of CEM-101 demonstrated comparable efficacy to the current standard of care, levofloxacin (commonly marketed as LevaquinTM), with an improved safety profile. Its second program is Taksta, which is developing in the U.S. as an oral treatment for acute bacterial skin and skin structure infections, or ABSSSI, frequently caused by Staphylococcus aureus, or S. aureus, including methicillin-resistant S. aureus, or MRSA, and beta-hemolytic streptococci. Taksta has successfully completed a Phase 2 clinical trial showing comparable efficacy and safety to linezolid (sold under the brand name Zyvox), the only oral antibiotic for treatment of MRSA approved by the U.S. Food and Drug Administration, or FDA. It expects to initiate pivotal Phase 3 trials for both programs in 2012. Its primary product includes CEM-101: The company is developing CEM-101, a fourth generation macrolide, to treat respiratory tract infections, including CABP and other serious infections; Taksta (Fusidic Acid): Taksta, its fusidic acid product candidate, is an oral antibiotic that company is developing in the U.S. for the treatment of ABSSSI, which is frequently caused by S. aureus, including MRSA, and beta-hemolytic streptococci. Fusidic acid is the only member of a unique class of antibiotics, called fusidanes, and has a mechanism of action that differs from any other antibiotic. It does not own or operate manufacturing facilities for the production of CEM-101, Taksta or other product candidates that might develop, nor do it has plans to develop own manufacturing operations in the foreseeable future. It is currently depend on third-party contract manufacturers for all of its required raw materials, API and finished products for its pre-clinical research and clinical trials. CEM-101, Taksta and any other anti
» More Articles for CEMP

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Cempra, Inc. to Report Second Quarter 2014 Financial and Operating Results, and Host Conference Call... Jul 22 2014
CEMPRA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Jul 02 2014
Coverage initiated on Cempra by Gabelli & Co Jun 20 2014
Cempra, Inc. to Present at JMP Securities Healthcare Conference Jun 17 2014
CEMPRA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Jun 03 2014
CEMPRA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... May 29 2014
CEMPRA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2014
Wall Street In and Out of Love with NASH Drug Developers May 13 2014
Cempra to present data on solithromycin at ECCMID May 11 2014
Cempra to Present Data on Solithromycin at ECCMID Highlighting Potential New Indications, Safety and... May 09 2014
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 08 2014
Cempra, Inc. to Present at Three Investor Conferences May 08 2014
CEMPRA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 06 2014
CEMPRA, INC. Financials May 06 2014
Cempra - Don't Throw The Baby Out With The Bathwater May 06 2014
Cempra Presents Late-Breaker on Solithromycin's Anti NASH Effects in an Animal Model at DDW 2014 May 06 2014
Is Cempra (CEMP) Ready to Breakout? May 01 2014
Cempra's CEO Discusses Q1 2014 Results - Earnings Call Transcript Apr 29 2014
CEMPRA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Apr 29 2014
Cempra, Inc. Reports First Quarter 2014 Financial and Operating Results Apr 29 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide